A large propensity-matched retrospective cohort study showed a small but statistically significant 7% increase in new-onset ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

A retrospective analysis of a large cohort of patients with diabetic macular edema showed high prevalence of bilateral ...

At AAO 2025, Genentech reported that vamikibart, a first-in-class IL-6–targeted antibody, led to rapid improvements in visual acuity and macular thickness in patients with uveitic macular edema, ...

A single-number metric from a handheld device outperformed dozens of other measurements for the prediction of ...

Ocugen Inc (($OCGN)) announced an update on their ongoing clinical study. Study Overview: Ocugen Inc. is conducting a Phase 1 study titled ‘A ...

DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years ...

David Eichenbaum, MD, FASRS, recalls an early-career case managing bilateral diabetic macular edema with frequent ...

Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

4D said it will receive an $85 million upfront cash payment from Otsuka and expects to receive at least $50 million of cost sharing from its partner over the next three years for development ...

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.